Month: March 2022

– Presented positive initial dose-escalation clinical data for SL-172154, including high target occupancy, dose-dependent immune activation, and unique safety profile in heavily pretreated cancer patients – – Presented positive initial dose-escalation clinical data for SL-279252, including anti-tumor activity, high target occupancy, and dose-dependent immune activation in heavily pretreated cancer patients – AUSTIN, TX and DURHAM, NC, March 15, 2022 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent business...

APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients APEX initial clinical data presentation expected in the first half of 2022 R&D Investor Event planned for April 8, 2022 Ended 2021 with $219.7 million in cash, sufficient to fund operations into 2024 CAMBRIDGE, Mass. and BOULDER, Colo., March 15, 2022 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the fourth quarter and year ended December 31, 2021. “In 2021, Cogent achieved substantial progress toward our goal of establishing bezuclastinib as a best-in-class KIT mutant inhibitor for systemic mastocytosis and gastrointestinal stromal tumor (GIST) patients,” said Andrew Robbins, President and CEO...

2021 revenue of $91.5 million, net income of $23 millionYear-end cash and equivalents of $129 millionExplosive growth in self-balancing scooter segment, up over 400%JINHUA, CHINA, March 15, 2022 (GLOBE NEWSWIRE) —  Kandi Technologies Group, Inc. (the “Company,” “we” or “Kandi”) (NASDAQ GS: KNDI), today announced its financial results for the full year ended December 31, 2021. Full Year 2021 Highlights • Total revenue was $91.5 million, compared to $76.9 million in 2020. • EV parts sales were $25.3million, compared to $40.6 million in 2020. • Off-road vehicles sales were $29.3 million, compared to $29.8 million in 2020. • EV product sales increased by 116% to $1.5 million, compared to $0.7 million in 2020. • Electric Scooters, Electric Self-Balancing Scooters and associated parts sales increased by 420.6% to $30.0 million,...

PLANO, Texas, March 15, 2022 (GLOBE NEWSWIRE) — Katapult Holdings, Inc. (“Katapult” or the “Company”) (NASDAQ: KPLT), an e-commerce-focused financial technology company, today reported its financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter and Full Year 2021 Financial and Operational Highlights:Recorded total revenue of $73.3 million in fourth quarter 2021 which was flat compared to prior year. Revenue for full year 2021 was $303.1 million as compared to $247.2 million in prior year, an increase of 23%.Added 20 new merchants in the fourth quarter 2021, despite ongoing macro challenges bringing our total to 102 new merchants for 2021, up 127% from a total of 45 new merchants in 2020.Achieved continued high customer satisfaction with Net Promoter Score of 54 as of December 31, 2021 and...

Total Revenues for Fiscal Year 2021 were $103.6 Million and Fourth Quarter 2021 Revenues were $31.5 Million. Fiscal Year 2022 Revenues are Expected to Range Between $125 Million to $135 Million, Representing a 20% to 30% Increase over 2021; 2022 EBITDA Margins Anticipated Between 12%–15%, Representing More Than 2.5X over 2021 EBITDA. Integration of Newly Acquired Portfolio of Four FDA-Approved Commercial Products is Progressing as Planned with Expanded Sales in International Markets. Advancing the Plan for the Opening of New U.S. Plasma Collection Centers. Company Expands U.S. Leadership Team with Multiple Key Hires to Drive Sales of Proprietary Products and Expansion of Plasma Collection Operations. Added Two New Biosimilar Product Candidates in Israel; Increasing the Expected Potential Collective Annual Peak Sales of the Entire...